Bildnachweis: Two hands connect puzzles. Copyright: Andrii Zastrozhnov – stock.adobe.com.
This news is based on a press release from NLC Health Ventures and BioSicence Valuation (BSV).
NLC Health Ventures and BioSicence Valuation (BSV) initiate a strategic collaboration to accelerate venture creation through best-in-class due diligence of early-stage bio-pharmaceutical assets.
NLC Health Ventures operates within the inherent complexity of bio-pharmaceutical innovations that require comprehensive risk assessment and corresponding corporate development strategies. BioScience Valuation is renowned for its excellence in evidence-based scientific, financial, and economic evaluations and modeling for the bio-pharmaceutical industry.
„We are very excited to partner with BioScience Valuation“ said Gábor Heltovics, Partner at NLC Health Ventures. „In our pursuit of groundbreaking innovations, this collaboration ensures that our bio-pharmaceutical ventures are of the highest scientific standards with excellent commercial viability.“
Joachim Greuel, Co-Founder and Managing Director at BioScience Valuation – said „We are thrilled to collaborate with the world-class, leading global venture builder NLC Health Ventures in order to found and develop life sciences start-ups that have the potential to significantly improve patients’ lives. NLC Health Ventures is known for their comprehensive and diligent scientific assessments of investment opportunities, and we are proud to further strengthen NLC’s investment decision processes.“
About NLC Health Ventures
NLC Health Ventures is the leading European early-stage healthcare investor and the world’s largest venture builder in healthtech. NLC identifies the best healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in biotech, medtech, and digital industries. NLC collaborates with academic and healthcare institutions and corporations. With its growing team of more than 80 professionals, four captive funds, and over 110 portfolio ventures built across 11 countries, we bring science to life and make the early-stage investible.
About BioScience Valuation
BioScience Valuation is a team of seasoned physicians, scientists, and finance experts with over 20 years of experience in pharma, biotech, and medtech. The team specializes in scientific as well as commercial assessments and provides evidence-based valuations, advising start-ups, maturing companies, and fully integrated firms in making value-driven investment decisions. BioScience Valuation’s comprehensive approach extends to asset prioritization, business strategy optimization, value-centric company reorganization, and negotiations involving acquisitions, licensing deals, financings, and exits.
Autor/Autorin
Urs Moesenfechtel
Urs Moesenfechtel, M.A., ist seit 2021 Redaktionsleiter der GoingPublic Media AG - Plattform Life Sciences und für die Themenfelder Biotechnologie und Bioökonomie zuständig. Zuvor war er u.a. Wissenschaftsredakteur für mehrere Forschungseinrichtungen tätig.
